Lawrence Steinman, MD, Stanford University, Stanford, CA, shares an update on the effects of ublituximab on relapse rate. Ublituximab is a novel monoclonal antibody targeting a unique epitope on the CD20 antigen. The Phase III ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) trials evaluated the efficacy and safety of ublituximab in patients with relapsing forms of multiple sclerosis (MS). Results demonstrated that ublituximab was superior to teriflunomide in preventing relapses; relapse rate and cumulative probability of relapse were significantly reduced with ublituximab compared to teriflunomide. The anti-CD20 monoclonal antibody is currently under FDA review for the treatment of relapsing MS. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

0 Comments

Up next

Autoplay

Low-Dose Aspirin Regimen Provides No Significant Health Benefits For Older Adults, Studies Find

6 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS

Up next

Language